Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

CAR T and CAR NK cells in multiple myeloma: Expanding the targets

(2020) Urvi A. Shah et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

(2020) Simon Harrison et al.   BLOOD

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

(2020) Deepu Madduri et al.   BLOOD

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

(2020) Jesus G. Berdeja et al.   BLOOD

OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma

(2020) Fredrik Schjesvold et al.   Future Oncology

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

(2020) Evangelos Terpos et al.   ANNALS OF HEMATOLOGY

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

(2020) Sham Mailankody et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

(2020) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

(2020) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

(2020) Marc S Raab et al.   Lancet Haematology

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

(2020) Paul G Richardson et al.   Lancet Haematology

Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy

(2020) Ewelina Grywalska et al.   Cells

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

(2020) Kodandaram Pillarisetti et al.   Blood Advances

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

(2019) Thomas Martin et al.   Blood Cancer Journal

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study

(2019) Janet A. Parsons et al.   BMC CANCER

Extramedullary disease in multiple myeloma – controversies and future directions

(2019) Sabina Sevcikova et al.   BLOOD REVIEWS

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

(2019) Joseph Mikhael et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib for relapsed and refractory multiple myeloma

(2019) K. Groen et al.   Cancer Management and Research

Facing lenalidomide-refractory myeloma

(2019) Michele Cavo   BLOOD

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

(2019) Meral Beksac et al.   HAEMATOLOGICA

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

Treatment of relapsed multiple myeloma: Evidence-based recommendations

(2019) Ceren Durer et al.   BLOOD REVIEWS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

(2019) Giovanni Palladini et al.   BLOOD

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

(2019) Jonathan L. Kaufman et al.   BLOOD

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Philippe Moreau et al.   BLOOD

AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment

(2019) Shih-Feng Cho et al.   Clinical Lymphoma Myeloma & Leukemia

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

(2019) Evangelos Eleutherakis-Papaiakovou et al.   Expert Review of Anticancer Therapy

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2019) Graham H Jackson et al.   Lancet Haematology

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival

(2018) Ingemar Turesson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

(2018) David S. Siegel et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

(2018) Philippe Moreau et al.   LANCET ONCOLOGY

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

(2018) Hiu Lam Agnes Yuen et al.   LEUKEMIA & LYMPHOMA

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palliative care specialists’ perceptions concerning referral of haematology patients to their services: findings from a qualitative study

(2018) Dorothy McCaughan et al.   BMC Palliative Care

Hospital end-of-life care in haematological malignancies

(2018) Yvan Beaussant et al.   BMJ Supportive & Palliative Care

Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreo-retinal lymphoma

(2018) Han W. Tun et al.   BLOOD

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial

(2018) Meletios A. Dimopoulos et al.   CANCER

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

(2018) Andrew Spencer et al.   HAEMATOLOGICA

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

(2018) Luciano J. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib

(2018) Michael Mian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

(2017) María-Victoria Mateos et al.   HAEMATOLOGICA

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

(2017) N J Bahlis et al.   LEUKEMIA

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

(2017) Malin Wickström et al.   Oncotarget

Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?

(2017) Thomas W. LeBlanc et al.   Current Hematologic Malignancy Reports

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

(2017) María-Victoria Mateos et al.   HAEMATOLOGICA

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

(2017) Sarah A Holstein et al.   Lancet Haematology

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Determinants of hospital death in haematological cancers: findings from a qualitative study

(2017) Dorothy McCaughan et al.   BMJ Supportive & Palliative Care

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

(2016) Rachid C. Baz et al.   BLOOD

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Multiple myeloma: patient outcomes in real-world practice

(2016) Kwee Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of relapsed and refractory multiple myeloma

(2016) P. Sonneveld et al.   HAEMATOLOGICA

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

(2016) A. Keith Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

(2016) P Moreau et al.   LEUKEMIA

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

(2016) Saad Usmani et al.   ONCOLOGIST

Treatment of relapsed and refractory multiple myeloma

(2016) P. Sonneveld et al.   HAEMATOLOGICA

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

(2016) Jesús F San-Miguel et al.   Lancet Haematology

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

(2016) Rakesh Popat et al.   Lancet Haematology

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

(2015) P. G. Richardson et al.   BLOOD

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKonerandomized dose selection trial

(2015) Steve Schey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

(2015) Mathew Weinstock et al.   BRITISH JOURNAL OF HAEMATOLOGY

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

(2015) M. Delforge et al.   HAEMATOLOGICA

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpretation of cytogenetic results in multiple myeloma for clinical practice

(2015) A M Rajan et al.   Blood Cancer Journal

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

(2015) M. Delforge et al.   HAEMATOLOGICA

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma

(2014) Annamaria Brioli et al.   BRITISH JOURNAL OF HAEMATOLOGY

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

(2014) Gordon Cook et al.   LANCET ONCOLOGY

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

(2014) J R Berenson et al.   LEUKEMIA

End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists

(2014) Oreofe O. Odejide et al.   Journal of Oncology Practice

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

(2013) Karin Jordan et al.   SUPPORTIVE CARE IN CANCER

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE